Gilead Sciences, Inc. bought $15M of RCUS
owner at Arcus Biosciences, Inc.. 1,363,636 shares at an average of $11.00, traded Feb 18, 2025, filed Feb 20, 2025.
Score components
- +12Role10% owner
- +25Trade size$15.0M at market
- 0Relative to holdingsHoldings up 4.5%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001062993-25-003084, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 18, 2025 | POpen-market purchase Common Stock | +1,363,636 | $11.00 | $15M | 31,424,760 | Feb 20, 2025 |
Related signals
Other insiders at Arcus Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | Arcus Biosciences, Inc. | Juan C. Jaen President | $681k 31,823 shares | -3% | |
| 21Weak | Arcus Biosciences, Inc. | Robert C. Goeltz II Chief Financial Officer | $153k 6,552 shares | -9% | |
| 45Moderate | Arcus Biosciences, Inc. | Terry J Rosen Chief Executive Officer | $1.2M 54,691 shares | -2% | |
| 32Weak | Arcus Biosciences, Inc. | Juan C. Jaen President | $467k 21,208 shares | -6% | |
| 36Weak | Arcus Biosciences, Inc. | Robert C. Goeltz II Chief Financial Officer | $279k 12,662 shares | -15% | |
| 32Weak | Arcus Biosciences, Inc. | Jennifer Jarrett Chief Operating Officer | $467k 21,208 shares | -10% | |
| 32Weak | Arcus Biosciences, Inc. | Alexander Azoy Chief Accounting Officer | $195k 8,832 shares | -32% | |
| 29Weak | Arcus Biosciences, Inc. | Carolyn C. Tang General Counsel | $318k 14,468 shares | -10% | |
| 27Weak | Arcus Biosciences, Inc. | Richard Markus Chief Medical Officer | $210k 9,546 shares | -13% | |
| 40Moderate | Arcus Biosciences, Inc. | Juan C. Jaen President | $2.1M 82,997 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.